GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 |
|
|
| Recruiting | 2/3 | 600 | Canada, US, RoW | Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan | Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT) | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer | 08/27 | 02/28 | | |
